Search

Your search keyword '"Inomata, Takayuki"' showing total 20 results
Start Over Author "Inomata, Takayuki" Journal international heart journal
20 results on '"Inomata, Takayuki"'

1. Optimal Timing of Serial 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography after Prednisolone Treatment Introduction for Cardiac Sarcoidosis

Author

Ishizuka, Mitsuo, primary, Kashimura, Takeshi, additional, Watanabe, Mitsuhiro, additional, Kase, Mayumi, additional, Sakai, Ryohei, additional, Okubo, Takeshi, additional, Fujiki, Shinya, additional, Takayama, Tsugumi, additional, Ishihara, Shiro, additional, Ozaki, Kazuyuki, additional, and Inomata, Takayuki, additional

Published
2023
Full Text
View/download PDF

2. The Risk of Ventricular Tachyarrhythmias in Patients with Antimitochondrial Antibodies-Related Noncardiac Diseases

Author

Ikami, Yasuhiro, primary, Izumi, Daisuke, additional, Hasegawa, Yuki, additional, Suzuki, Naomasa, additional, Sakaguchi, Yuta, additional, Hakamata, Takahiro, additional, Otsuki, Sou, additional, Yagihara, Nobue, additional, Iijima, Kenichi, additional, Kashimura, Takeshi, additional, Chinushi, Masaomi, additional, Minamino, Tohru, additional, and Inomata, Takayuki, additional

Published
2022
Full Text
View/download PDF

6. Importance of Early Diagnosis of Cardiac Sarcoidosis in Patients with Complete Atrioventricular Block

Author

Kaida, Toyoji, primary, Inomata, Takayuki, additional, Minami, Yoshiyasu, additional, Yazaki, Mayu, additional, Fujita, Teppei, additional, Iida, Yuichiro, additional, Ikeda, Yuki, additional, Nabeta, Takeru, additional, Ishii, Shunsuke, additional, Naruke, Takashi, additional, Maekawa, Emi, additional, Koitabashi, Toshimi, additional, and Ako, Junya, additional

Published
2018
Full Text
View/download PDF

7. Hemodilution after Initial Treatment in Patients with Acute Decompensated Heart Failure

Author

Fujita, Teppei, primary, Inomata, Takayuki, additional, Yazaki, Mayu, additional, Iida, Yuichiro, additional, Kaida, Toyoji, additional, Ikeda, Yuki, additional, Nabeta, Takeru, additional, Ishii, Shunsuke, additional, Maekawa, Emi, additional, Yanagisawa, Tomoyoshi, additional, Koitabashi, Toshimi, additional, Takeuchi, Ichiro, additional, and Ako, Junya, additional

Published
2018
Full Text
View/download PDF

9. Who Needs Longer Tolvaptan Treatment?

Author

Kinugawa, Koichiro, primary, Inomata, Takayuki, additional, Sato, Naoki, additional, Yasuda, Moriyoshi, additional, Shimakawa, Toshiyuki, additional, Bando, Kosuke, additional, and Fukuta, Yasuhiko, additional

Published
2017
Full Text
View/download PDF

15. End-Tidal Carbon Dioxide Concentration Can Estimate the Appropriate Timing for Weaning Off From Extracorporeal Membrane Oxygenation for Refractory Circulatory Failure

Author

Naruke, Takashi, primary, Inomata, Takayuki, additional, Imai, Hiroshi, additional, Yanagisawa, Tomoyoshi, additional, Maekawa, Emi, additional, Mizutani, Tomohiro, additional, Osaka, Tsutomu, additional, Shinagawa, Hisahito, additional, Koitabashi, Toshimi, additional, Nishii, Mototsugu, additional, Takeuchi, Ichiro, additional, Takehana, Hitoshi, additional, Aoyama, Naoyoshi, additional, and Izumi, Tohru, additional

Published
2010
Full Text
View/download PDF

20. Optimal Timing of Serial 18 F-Fluoro-2-Deoxyglucose Positron Emission Tomography after Prednisolone Treatment Introduction for Cardiac Sarcoidosis.

Author

Ishizuka M, Kashimura T, Watanabe M, Kase M, Sakai R, Okubo T, Fujiki S, Takayama T, Ishihara S, Ozaki K, and Inomata T

Subjects
Humans, Prednisolone therapeutic use, Fluorodeoxyglucose F18, Radiopharmaceuticals, Positron-Emission Tomography methods, Retrospective Studies, Cardiomyopathies diagnostic imaging, Cardiomyopathies drug therapy, Sarcoidosis diagnostic imaging, Sarcoidosis drug therapy, Myocarditis
Abstract

Immunosuppressive therapy with prednisolone (PSL) is the first-line treatment for cardiac sarcoidosis (CS), and 18 F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) is used to evaluate its efficacy to guide treatment. However, the appropriate timing of FDG-PET in CS remains unknown. This single-center, retrospective, observational study included 15 consecutive CS patients who underwent 3 serial FDG-PET scans (at baseline, in the early phase [1-2 months after PSL introduction], and in the late phase [≥ 5 months after PSL introduction with a maintenance dose of PSL]). We adhered to the PSL tapering protocol by the Japanese Circulation Society even when early FDG-PET showed positive results (SUVmax ≥ 4.0). No patient died during the 908 (644-1600) days of observation. Negative results in the late phase were observed in 3 of 6 early-positive patients, and 3 of 9 early-negative patients showed positive results in the late phase. Changes in echocardiographic parameters from baseline to the late phase were significantly better in late-negative patients than in late-positive patients (left ventricular end-diastolic diameter: -0.7 (-9.3-[-0.5]) mm versus +3.5 (0.8-7.5) mm, P = 0.039; left ventricular end-systolic diameter: -4.2 (-6.9-[-0.1]) mm versus +5.1 (0.5-7.0) mm, P = 0.015; left ventricular ejection fraction: +4.7% (-1.0-9.0%) versus -1.5% (-11.3-1.5%), P = 0.045) ), although early FDG-PET did not predict those consequent changes. An interval of ≥ 5 months after introducing the PSL with a maintenance dose of PSL is long enough for FDG-PET to reflect consequent left ventricular functions, while an interval of 1-2 months can be too short.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results